Travere Therapeutics, Inc. (TVTX)
51.56
-0.48
(-0.92%)
USD |
NASDAQ |
Nov 12, 16:00
52.57
+1.01
(+1.96%)
After-Hours: 20:00
Travere Therapeutics Free Cash Flow (Quarterly) : 69.45M for Sept. 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 69.45M |
| June 30, 2026 | 37.00M |
| March 31, 2026 | -62.54M |
| December 31, 2025 | 41.81M |
| September 30, 2025 | -0.871M |
| June 30, 2025 | -7.338M |
| March 31, 2025 | -53.98M |
| December 31, 2024 | -45.28M |
| September 30, 2024 | -50.70M |
| June 30, 2024 | -52.24M |
| March 31, 2024 | -125.47M |
| December 31, 2023 | -76.00M |
| September 30, 2023 | -64.06M |
| June 30, 2023 | -73.13M |
| March 31, 2023 | -109.08M |
| December 31, 2022 | -58.84M |
| September 30, 2022 | -47.16M |
| June 30, 2022 | -48.27M |
| March 31, 2022 | -60.59M |
| December 31, 2021 | -32.08M |
| September 30, 2021 | 26.69M |
| June 30, 2021 | 2.189M |
| March 31, 2021 | -35.74M |
| December 31, 2020 | -22.47M |
| September 30, 2020 | -0.18M |
| Date | Value |
|---|---|
| June 30, 2020 | -10.89M |
| March 31, 2020 | -33.77M |
| December 31, 2019 | -8.472M |
| September 30, 2019 | -18.34M |
| June 30, 2019 | -22.50M |
| March 31, 2019 | -24.47M |
| December 31, 2018 | -7.431M |
| September 30, 2018 | -7.744M |
| June 30, 2018 | -6.494M |
| March 31, 2018 | -22.99M |
| December 31, 2017 | -3.794M |
| September 30, 2017 | 2.463M |
| June 30, 2017 | 1.816M |
| March 31, 2017 | -7.091M |
| December 31, 2016 | -10.99M |
| September 30, 2016 | 1.956M |
| June 30, 2016 | 1.684M |
| March 31, 2016 | -6.166M |
| December 31, 2015 | -4.273M |
| September 30, 2015 | -2.452M |
| June 30, 2015 | 6.499M |
| March 31, 2015 | -7.358M |
| December 31, 2014 | -9.176M |
| September 30, 2014 | -15.66M |
| June 30, 2014 | -14.95M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | 545.80M |
| TG Therapeutics, Inc. | 44.94M |
| Viridian Therapeutics, Inc. | -93.14M |
| BioMarin Pharmaceutical, Inc. | 165.35M |
| Emergent BioSolutions, Inc. | 96.80M |